Source comparison
BPC-157 for Restless Leg Syndrome Research: Mechanism Comparison
Dopamine Agonists (pramipexole, ropinirole) Direct D2/D3 receptor stimulation Increases receptor activation without increasing endogenous synthesis No direct effect 30–50% within 5 years FDA-approved first-line therapy Alpha-2-Delta Ligands (gabapentin, pregab
This comparison does not assign a generated winner or score.
- Dopamine Agonists (pramipexole, ropinirole)
- Direct D2/D3 receptor stimulation
- Increases receptor activation without increasing endogenous synthesis
- No direct effect
- 30–50% within 5 years
- FDA-approved first-line therapy
- Alpha-2-Delta Ligands (gabapentin, pregabalin)
- Calcium channel modulation reducing excitatory neurotransmission
- Indirectly enhances inhibitory tone
- Not documented
- Recommended for patients with comorbid pain or augmentation
- Iron Supplementation
- Restores tyrosine hydroxylase cofactor availability
- Enhances endogenous dopamine synthesis capacity
- Not applicable
- Recommended when ferritin <75 µg/L
- BPC-157 (investigational)
- Upregulation of tyrosine hydroxylase; GABA-A receptor density increase
- Supports endogenous synthesis rather than receptor stimulation
- Direct receptor upregulation in preclinical models
- Unknown. No long-term human data
- Preclinical only; no human RLS trials published